Created On: 2020-07-15
Record Count: 9
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 301197
IPSCIO Record ID: 257032
Through the complementary mechanisms of action of inhibition of cholesterol synthesis (bempedoic acid) and inhibition of cholesterol absorption (ezetimibe), the bempedoic acid / ezetimibe combination pill is our lead, non-statin, orally available, once-daily, LDL-C lowering therapy. Inhibition of ATP Citrate Lyase by bempedoic acid reduces cholesterol biosynthesis.
IPSCIO Record ID: 294283
Licensor grants to an exclusive license in the Territory under the Patent Rights to develop, make, have made, import, export, use, distribute, market, promote, offer for sale and sell the Licensed Compound, solely for use as an active ingredient in Licensed Products and Licensed Products.
BT/6 shall mean any form, including, without limitation, any salt, hydrate, crystalline structure or the like, of the small molecule compound identified by the chemical name B,B-tetramethyl hexadecane-a, (.)-dioic acid.
BT 2000 shall mean the compounds covered by PCT Patent W098/30530 including, without limitation, B, B -tetramethyloctadecanedioic acid.
Licensed Compound shall mean BT16.
The patents include Use of alpha, omega-dicarboxylic acids as fibrinogen sinkers, and, Pharmaceutical compositions containing carboxylic acids and derivatives thereof, and, Methods of administering 3,3,14,14 terramethyl hexadecane 1,16 dioic acid.
BT16 was found to have a potent efficacy of suppressing triglyceride levels in animal and human studies. Further studies demonstrated that it has also insulin-sensitizing properties and the possibility of this compound being developed as a metabolic syndrome therapy in the future has been suggested.
Dyslipidemia is an abnormal amount of lipids (e.g. triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Dyslipidemia increases the chance of clogged arteries (atherosclerosis) and heart attacks, stroke, or other circulatory concerns, especially in smokers.
Licensee possesses extensive capabilities in the development and commercialization of pharmaceutical products in Japan and in certain countries in Asia. Licensor is a clinical-stage pharmaceutical company engaged in discovering and developing novel RNAi interference or RNAi-based therapeutics.
IPSCIO Record ID: 258520
IPSCIO Record ID: 249742
Designated Compound means: BMS-201,038; prodrugs or metabolites of BMS-201,038, to the extent any such prodrug or metabolite is covered by a composition claim in a Composition Patent; and stereoisomers, hydrates, anhydrides, solvates, salt forms, or polymorphs of BMS-201,038 or any compounds; furthermore, in the case of a prodrug or metabolite as referred to above, the compound in question will constitute a Designated Compound hereunder only if the making, use or sale of such compound is necessary for or results from the making, use and sale of BMS-210,038 within the Field of Use.
The University completed a Phase II clinical trial of lomitapide for the treatment of patients with called homozygous familial hypercholesterolemia, or HoFH.
Licensee's lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor, or MTP-I, which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. Licensee is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia, or HoFH. These patients are at very high risk of experiencing life threatening events at an early age as a result of extremely elevated cholesterol levels in the blood. Licensee believe that lomitapide, either on a stand-alone basis or in combination with other drugs, has the potential to help these patients achieve recommended target levels of low-density lipoprotein cholesterol, or LDL-C.
IPSCIO Record ID: 123666
Hypercholesterolemia, also called dyslipidemia, is the presence of high levels of cholesterol in the blood.
IPSCIO Record ID: 233152
Apolipoprotein E (Apo E) is in a class of protein that occurs throughout the body. Apo E is essential for the normal metabolism of cholesterol and triglycerides. After a meal, the postprandial (or post-meal) lipid load is packaged in lipoproteins and secreted into the blood stream. Apo E targets cholesterol and triglyceride rich lipoproteins to specific receptors in the liver, decreasing the levels in the blood. Elevated plasma cholesterol and triglycerides are independent risk factors for atherosclerosis, the buildup of cholesterol rich lesions and plaques in the arteries. Atherosclerosis is the major cause of cardiovascular disease, peripheral artery disease and cerebral artery disease, and can cause heart attack, loss of limbs and stroke. Defective lipid metabolism also plays an important role in the development of adult onset diabetes mellitus (Type 2 diabetes), and diabetics are particularly vulnerable to atherosclerosis, heart and peripheral artery diseases.
IPSCIO Record ID: 249743
Licensed Compound means the compound known as Bay 13-9952 and identified as implitapide, and any metabolic precursors, prodrugs, isomers (chiral and otherwise), metabolites, hydrates, anhydrides, solvates, salt forms, free acids or bases, esters, amides, ethers, complexes, conjugates or polymorphs of any compounds.
Lipid disorder means a high blood levels of low-density lipoprotein (LDL) cholesterol, fats called triglycerides, or both. Lipid disorders, such as high cholesterol, can increase the risk of heart problems, such as heart attack.
IPSCIO Record ID: 300431
Licensee of France will transfer to the Company certain assets relating to the commercialization of Praluent in the United States. The Company, at its sole cost, is solely responsible for the development and commercialization of Praluent in the United States, and Licensee, at its sole cost, is solely responsible for the development and commercialization of Praluent outside of the United States.
– to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease.
– as an adjunct to diet, alone or in combination with other lipid-lowering therapies (e.g., statins, ezetimibe), for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C).